NEW YORK, May 11, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Puma Biotechnology, Inc. ("Puma Biotechnology") (NASDAQ:PBYI) between February 29, 2016 and May 4, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Central District of California. To get more information go to:
http://www.zlk.com/pslra-sb/puma-biotechnology-inc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) the Company did not anticipate that the U.S. Food and Drug Administration (“FDA”) would ultimately approve PB272 (“neratinib”) for the treatment of breast cancer; (ii) as such, Puma Biotechnology had overstated the drug’s approval prospects and/or commercial viability; and (iii) as a result, Puma Biotechnology’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Puma Biotechnology you have until July 7, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Washington Post Publisher Will Lewis Steps Down After Layoffs
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 



